主页 > 医学文档 >
【medical-news】ASPECT研究：糖尿病患者对不同剂量
The Effect of Aspirin Dosing on Platelet Function in Diabetic and Non-Diabetic Patients: An Analysis from the ASpirin-Induced Platelet EffeCT (ASPECT) Study
Objective: Diabetic patients may have a higher prevalence of platelet aspirin resistance (AR) than non-diabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and non-diabetic patients.
Research Design and Methods: We examined the effect of aspirin (81, 162 and 325mg/day for 4 weeks each) on platelet aspirin responsiveness in 120 stable outpatients (30 diabetic patients, 90 non-diabetic patients) with coronary artery disease (CAD) using light transmittance aggregometry (LTA); VerifyNow; platelet function analyzer (PFA)-100; and levels of urinary 11-dehydro(dh)-thromboxane(Tx)B2.
Results: In the total group, a low prevalence (0-2%) of AR was observed with all aspirin doses as determined by AA-induced LTA. AR was higher at the 81mg dose in diabetic versus non-diabetic patients using collagen-induced LTA (27% vs. 4%, p=0.001), VerifyNow (13% vs. 3%, p=0.05) and urinary 11dh-TxB2 (37% vs. 17%, p=0.03). Diabetic patients treated with 81mg exhibited higher platelet function measured by VerifyNow, collagen- and ADP-induced LTA, and 11-dh-TxB2 levels (p 0.02 for all comparisons). Higher aspirin doses significantly inhibited platelet function and decreased AR in diabetic patients (p<0.05).
Conclusions: Diabetic patients with CAD treated with 81mg aspirin exhibit a higher prevalence of AR and have significantly higher ADP- and collagen-induced platelet aggregation, 11-dh-TxB2 levels and aspirin reaction units measured by VerifyNow compared to non-diabetic patients. Increased aspirin dosing resulted in similar rates of resistance and platelet function levels between groups. These findings indicate that diabetic patients exhibit a global high platelet reactivity phenotype that may be partially overcome by higher aspirin doses. The Effect of Aspirin Dosing on Platelet Function in Diabetic and Non-Diabetic Patients: An Analysis from the ASpirin-Induced Platelet EffeCT (ASPECT) Study
阿斯比林剂量，对糖尿病人和非糖尿病人的血小板功能的影响，来自阿斯比林降低血小板功能的影响分析
Objective: Diabetic patients may have a higher prevalence of platelet aspirin resistance (AR) than non-diabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and non-diabetic patients.
目的：糖尿病人对血小板阿斯比林阻抗platelet aspirin resistance (AR)比非糖尿病人高。研究目的是分析不同的阿斯比林剂量对糖尿病人和非糖尿病人的血小板阿斯比林反应
Research Design and Methods: We examined the effect of aspirin (81, 162 and 325mg/day for 4 weeks each) on platelet aspirin responsiveness in 120 stable outpatients (30 diabetic patients, 90 non-diabetic patients) with coronary artery disease (CAD) using light transmittance aggregometry (LTA); VerifyNow; platelet function analyzer (PFA)-100; and levels of urinary 11-dehydro(dh)-thromboxane(Tx)B2.
研究设计和方法，对120个稳定的门诊冠心病人（糖尿病30，非糖尿病90）使用light transmittance aggregometry (LTA); 检查阿斯比林的影响，用量为4个星期内，每天81, 162 and 325mg。 VerifyNow；血小板功能分析 (PFA)-100，尿液11脱水凝血恶烷11-dehydro(dh)-thromboxane(Tx)B2水平.
Results: In the total group, a low prevalence (0-2%) of AR was observed with all aspirin doses as determined by AA-induced LTA. AR was higher at the 81mg dose in diabetic versus non-diabetic patients using collagen-induced LTA (27% vs. 4%, p=0.001), VerifyNow (13% vs. 3%, p=0.05) and urinary 11dh-TxB2 (37% vs. 17%, p=0.03). Diabetic patients treated with 81mg exhibited higher platelet function measured by VerifyNow, collagen- and ADP-induced LTA, and 11-dh-TxB2 levels (p 0.02 for all comparisons). Higher aspirin doses significantly inhibited platelet function and decreased AR in diabetic patients (p<0.05).
结果：总体组，所有的阿斯比林剂量由 LTA诱导滴定，观察血小板阿斯比林阻抗platelet aspirin resistance (AR)的低流行 (0-2%) 。81毫克组，用胶原质诱导LTA，糖尿病人的血小板阿斯比林阻抗AR，高于非糖尿病人(27% vs. 4%, p=0.001)； VerifyNow，(13% vs. 3%, p=0.05) ；尿液 11dh-TxB2 (37% vs. 17%, p=0.03). 用81毫克治疗的糖尿病人展示，用VerifyNow, 测定，血小板功能较高。, collagen- and ADP-induced LTA, and 11-dh-TxB2 levels (p 0.02 for all comparisons)也较高. 较大剂量的阿斯比林，明显抑制血小板功能。减少血小板阿斯比林阻抗platelet aspirin resistance (AR)
Conclusions: Diabetic patients with CAD treated with 81mg aspirin exhibit a higher prevalence of AR and have significantly higher ADP- and collagen-induced platelet aggregation, urinary 11dh-TxB2 , aspirin reaction units measured by VerifyNow compared to non-diabetic patients. Increased aspirin dosing resulted in similar rates of resistance and platelet function levels between groups. These findings indicate that diabetic patients exhibit a global high platelet reactivity phenotype that may be partially overcome by higher aspirin doses.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-10 17:28
医学,生命科学网